Premium
Muramyl dipeptide and anti‐ CD 10 monoclonal antibody immunoconjugate enhances anti‐leukemia immunity of T lymphocytes
Author(s) -
Wang Lingzhen,
Zhang Li,
Wang LingLi,
Lu Yuan,
Chen Lei,
Sun Yan,
Zhao Hongguo,
Song Liang,
Sun LiRong
Publication year - 2016
Publication title -
apmis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 88
eISSN - 1600-0463
pISSN - 0903-4641
DOI - 10.1111/apm.12560
Subject(s) - muramyl dipeptide , immunoconjugate , leukemia , monoclonal antibody , cytotoxic t cell , immunology , medicine , minimal residual disease , cancer research , antibody , chemistry , immune system , in vitro , biochemistry
It is necessary to completely eliminate minimal residual disease ( MRD ) to cure acute leukemia. Monoclonal antibodies ( MA b) have been shown to be effective to eliminate MRD . In this study we aimed to investigate the effect of anti‐ CD 10 MA b conjugated to muramyl dipeptide immunoconjugate ( MDP ‐Ab) on the function of lymphocytes and activated lymphocytes using leukemia xenografts in nude mice as a model. Peripheral blood mononuclear cells were isolated from children with acute lymphoblastic leukemia and induced into dendritic cells ( DC s) and lymphocytes. Cytotoxic activity of lymphocytes was detected by LDH release assay. Leukemia xenografts in nude mice were established to assess tumor growth. We found that the killing rate was significantly higher in MDP ‐Ab group, LPS group and MDP ‐Ab+ LPS group than in control group, and was the highest in MDP ‐Ab+ LPS group. Tumor‐bearing mice in MDP ‐Ab group showed obvious coagulation necrosis. In conclusion, our data suggest that MDP ‐Ab could effectively prime DC s to improve the anti‐tumor immunity of T lymphocytes and inhibit the tumor growth. MDP ‐Ab may be used as suitable candidate for eliminating residual leukemia cells to prevent relapse.